Developing Microbials to Fight Extended-spectrum Beta-lactamase (ESBL)-Producing Escherichia Coli
- Conditions
- Extended Spectrum Beta Lactamases (ESBL) E. Coli
- Registration Number
- NCT04764500
- Lead Sponsor
- University Hospital, Basel, Switzerland
- Brief Summary
This study is to identify and isolate well-defined microbials (non-ESBL E. coli) in an observational setting exploring natural gastrointestinal decolonization of humans colonized with ESBL E. coli.
- Detailed Description
Antibiotic resistance is a severe threat to contemporary medicine. Effective approaches to fight multi-drug resistant pathogenic bacteria are needed.
This clinical observational study is to investigate whether express extended spectrum beta lactamases (ESBL) E. coli colonizing the human gut can be out-competed by other, ideally pan-sensitive strains (non-ESBL E. coli).
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 39
- travelling to Southeast Asia (India, Bhutan, Nepal, Bangladesh, Myanmar, Thailand, Laos, Cambodia, Vietnam) for a maximum of 4 weeks.
- other travelling destinations than mentioned above
- antibiotic use at the first sampling time
- Participants who are not colonized will serve as a control group for microbiome comparison
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method proportion of patients being "naturally" decolonized from ESBL E. coli 18 months proportion of patients being "naturally" decolonized from ESBL E. coli at the end of the study period at 18 months
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University Hospital Basel, Division of Clinical Microbiology
🇨🇭Basel, Switzerland
University Hospital Basel, Division of Clinical Microbiology🇨🇭Basel, Switzerland